Shionogi's zatolmilast demonstrated an efficacy signal in one FXS study in adults, but it missed its primary endpoints across the programme.
Faced with growing dominance from China, governments are transforming clinical trial frameworks to boost R&D activity.
QuartzBio has secured a strategic investment and majority ownership from Eir Partners to expedite its clinical trial intelligence platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results